IL224071B - 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors - Google Patents

5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors

Info

Publication number
IL224071B
IL224071B IL224071A IL22407112A IL224071B IL 224071 B IL224071 B IL 224071B IL 224071 A IL224071 A IL 224071A IL 22407112 A IL22407112 A IL 22407112A IL 224071 B IL224071 B IL 224071B
Authority
IL
Israel
Prior art keywords
sphingosine
biphenyl
ligands
receptors
phenyl
Prior art date
Application number
IL224071A
Other languages
English (en)
Hebrew (he)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of IL224071B publication Critical patent/IL224071B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL224071A 2010-07-08 2012-12-31 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors IL224071B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10168833 2010-07-08
US36274610P 2010-07-09 2010-07-09
PCT/EP2011/061372 WO2012004287A1 (en) 2010-07-08 2011-07-06 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors

Publications (1)

Publication Number Publication Date
IL224071B true IL224071B (en) 2018-06-28

Family

ID=42341535

Family Applications (1)

Application Number Title Priority Date Filing Date
IL224071A IL224071B (en) 2010-07-08 2012-12-31 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors

Country Status (15)

Country Link
US (1) US9029405B2 (https=)
EP (1) EP2590956B1 (https=)
JP (1) JP6014589B2 (https=)
KR (1) KR20140003379A (https=)
CN (1) CN103097365B (https=)
AR (1) AR082132A1 (https=)
AU (1) AU2011275854B2 (https=)
CA (1) CA2804473C (https=)
EA (1) EA201300092A1 (https=)
ES (1) ES2586145T3 (https=)
IL (1) IL224071B (https=)
MX (1) MX2012015021A (https=)
SG (1) SG186872A1 (https=)
TW (1) TW201206429A (https=)
WO (1) WO2012004287A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
JP7679384B2 (ja) * 2019-12-23 2025-05-19 シトリクス・セラピューティクス・リミテッド 抗炎症特性を有するカルボン酸誘導体
KR20220158743A (ko) * 2020-03-27 2022-12-01 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
US20240228448A1 (en) * 2021-03-31 2024-07-11 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (s1p1), imaging of s1p1, and processes for preparation thereof
KR102658761B1 (ko) * 2021-04-14 2024-04-19 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법
US12571867B2 (en) 2022-04-14 2026-03-10 United States Pharmacopeial Convention Nuclear magnetic resonance analysis systems and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711792B1 (de) 1994-11-05 1999-03-10 BASF Aktiengesellschaft Melaminharze
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
BRPI0612028A2 (pt) * 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
RU2009115963A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
ES2622423T3 (es) * 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives

Also Published As

Publication number Publication date
JP6014589B2 (ja) 2016-10-25
CN103097365A (zh) 2013-05-08
AU2011275854B2 (en) 2015-08-27
EA201300092A1 (ru) 2013-06-28
ES2586145T3 (es) 2016-10-11
AR082132A1 (es) 2012-11-14
AU2011275854A1 (en) 2013-02-21
WO2012004287A1 (en) 2012-01-12
CA2804473C (en) 2019-04-02
JP2013530202A (ja) 2013-07-25
TW201206429A (en) 2012-02-16
US9029405B2 (en) 2015-05-12
CA2804473A1 (en) 2012-01-12
KR20140003379A (ko) 2014-01-09
SG186872A1 (en) 2013-02-28
US20130116289A1 (en) 2013-05-09
MX2012015021A (es) 2013-04-03
EP2590956B1 (en) 2016-05-04
EP2590956A1 (en) 2013-05-15
CN103097365B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
IL242279A0 (en) Compounds of 3-chloro-3]-n-(pyrimidine-2-ylamino)phenyl]substituted propanamide and their salts
SI2694508T1 (sl) Soli substituiranega 2,3-dihidroimidazo(1,2-C)kinazolina
ZA201206440B (en) [5,6]heterocyclic compound
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
PL2520575T3 (pl) Związek 1,3,4-oksadiazolo-2-karboksyamidowy
IL224071B (en) 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors
ZA201404294B (en) Substituted 1,2,5-oxadiazole compounds and their use as herbicides
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
AP2014007670A0 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
ZA201404296B (en) Substituted 1,2,5-oxadiazole compounds and their use as herbicides ii
ZA201404331B (en) Substituted 1,2,5-oxadiazole compounds and their use as herbicides iii
IL232917A (en) Annals of 5 - (3-aminophenyl) -5-alkyl-6,5-dihydro-2h [4,1] oxazin-3-amine
ZA201303116B (en) Imine substituted 2,4-diaryl-pyrroline derivatives as pesticides
PL2912030T3 (pl) Ulepszony sposób wytwarzania 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4- trifluorometylopirydyno-2-aminy
ZA201306229B (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines
BR112012016786A2 (pt) Processos para preparar 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4- trifluorometoxibenzil)-2
IL231468A0 (en) 3,1-diaryl-converted heterocyclic pesticides
ZA201404515B (en) Agricultural machine with an improved terrain following for the work elements
IL214110A0 (en) 2,3-diaryl-or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
PT2523963E (pt) Derivados de oxazolopirimidina substituídos em 2,5 como agonistas do edg-1
EP2443112A4 (en) THIAZOLE OR THIADIAZOLE DERIVATIVES FOR USE AS SPHINGOSIN-1-PHOSPHATE-1 (S1P1) RECEPTOR AGONISTS
PL2771328T3 (pl) Sposób otrzymywania 1,2-benzizotiazolin-3-onu
EP2547662A4 (en) PYRIMIDINE DERIVATIVES FOR USE AS AGONISTS OF SPHINGOSIN 1-PHOSPHATE 1 (S1P1) RECEPTORS
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
IL222929A0 (en) Process for preparing substituted 1, 3 - dihydro - 2h - indol - 2 - ones

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed